HC Wainwright Forecasts Strong Price Appreciation for Senseonics (NYSE:SENS) Stock

Senseonics (NYSE:SENS) had its price objective boosted by equities research analysts at HC Wainwright to $18.50 in a report released on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s target price would suggest a potential upside of 207.82% from the stock’s current price.

SENS has been the subject of a number of other research reports. TD Cowen cut their price objective on shares of Senseonics from $25.00 to $15.00 and set a “buy” rating for the company in a report on Wednesday. Lake Street Capital upgraded Senseonics to a “strong-buy” rating in a research report on Thursday, July 17th. Barclays restated an “overweight” rating and issued a $31.00 price target (up previously from $1.50) on shares of Senseonics in a research note on Wednesday. Finally, Stifel Nicolaus started coverage on Senseonics in a research report on Tuesday, October 21st. They set a “hold” rating and a $9.00 price target on the stock. Two research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $22.70.

Senseonics Stock Performance

Shares of NYSE SENS traded down $0.21 during midday trading on Thursday, reaching $6.01. 718,839 shares of the stock were exchanged, compared to its average volume of 424,332. The company has a quick ratio of 2.38, a current ratio of 2.47 and a debt-to-equity ratio of 59.17. The firm has a market cap of $244.81 million, a price-to-earnings ratio of -46.23 and a beta of 0.79. The firm has a 50-day simple moving average of $8.43 and a two-hundred day simple moving average of $9.97. Senseonics has a twelve month low of $5.00 and a twelve month high of $28.00.

Institutional Investors Weigh In On Senseonics

Several institutional investors have recently bought and sold shares of SENS. Smith Salley Wealth Management increased its stake in Senseonics by 10.9% during the 3rd quarter. Smith Salley Wealth Management now owns 61,000 shares of the company’s stock worth $27,000 after buying an additional 6,000 shares in the last quarter. CTC Alternative Strategies Ltd. acquired a new stake in shares of Senseonics in the first quarter worth approximately $31,000. IFP Advisors Inc increased its position in shares of Senseonics by 120.9% during the first quarter. IFP Advisors Inc now owns 47,500 shares of the company’s stock worth $31,000 after purchasing an additional 26,000 shares in the last quarter. Elite Life Management LLC purchased a new stake in shares of Senseonics during the second quarter worth approximately $36,000. Finally, HBK Sorce Advisory LLC acquired a new position in Senseonics in the 3rd quarter valued at $39,000. 12.36% of the stock is currently owned by institutional investors and hedge funds.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.